PTLD
MCID: PST046
MIFTS: 53

Post-Transplant Lymphoproliferative Disease (PTLD)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Post-Transplant Lymphoproliferative Disease

MalaCards integrated aliases for Post-Transplant Lymphoproliferative Disease:

Name: Post-Transplant Lymphoproliferative Disease 20 58 37
Post-Transplant Lymphoproliferative Disorder 20 70
Ptld 20 58

Characteristics:

Orphanet epidemiological data:

58
post-transplant lymphoproliferative disease
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 D47.9
UMLS via Orphanet 71 C0432487
Orphanet 58 ORPHA70568
UMLS 70 C0432487

Summaries for Post-Transplant Lymphoproliferative Disease

GARD : 20 Post-transplant lymphoproliferative disease (PTLD) is a complication of transplantation in which there is uncontrolled growth of lymphocytes. It occurs in people whose immune systems have been intentionally suppressed due to having a solid organ transplant or hematopoietic stem cell transplant. The severity of PTLD can range from causing a mild, noncancerous (benign) overgrowth of tissue, to causing a life-threatening, cancerous (malignant) form of lymphoma. Common signs and symptoms are often vague, such as feeling unwell (malaise), fever, weight loss, night sweats, fatigue, and swollen lymph nodes. Additional symptoms depend on the organs or body part(s) affected. The digestive tract, central nervous system, and/or transplanted organ are often involved. PTLD is often caused by Epstein-Barr virus (EBV), which infects lymphocytes called B-cells. Most people get EBV in childhood, but the virus becomes "inactive" because the immune system keeps it under control. In people with PTLD due to EBV, a weakened immune system may allow EBV to reactivate in infected B- cells, leading to their uncontrolled growth. In some cases, EBV from the transplant donor is reactivated in the recipient. PTLD can also occur if a recipient first becomes infected with EBV after the transplant. The reason that PTLD develops in people without EBV is not clear. PTLD is diagnosed by immunophenotyping a biopsy of an involved lymph node or other affected tissue. Additional tests such as blood tests, imaging tests, or bone marrow biopsy may be needed to determine the location(s) and extent of the disease in the body. Treatment recommendations may vary among people with PTLD but typically include lowering the dose of immunosuppresive drugs to allow the immune system to fight the EBV-infected cells. There are no therapies approved by the FDA to treat PTLD, but additional treatment options include using rituximab, surgery to remove affected tissue, radiation therapy, immunotherapy, and chemotherapy. Other treatments are being studied in clinical trials.

MalaCards based summary : Post-Transplant Lymphoproliferative Disease, also known as post-transplant lymphoproliferative disorder, is related to graft-versus-host disease and diffuse large b-cell lymphoma. An important gene associated with Post-Transplant Lymphoproliferative Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Ketamine and Iron have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone marrow and t cells, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Increased viability with MLN4924 (a NAE inhibitor)

Wikipedia : 73 Post-transplant lymphoproliferative disorder (PTLD) is the name given to a B-cell proliferation due to... more...

Related Diseases for Post-Transplant Lymphoproliferative Disease

Diseases related to Post-Transplant Lymphoproliferative Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 557)
# Related Disease Score Top Affiliating Genes
1 graft-versus-host disease 30.7 TNF IL6 IL1A IL10
2 diffuse large b-cell lymphoma 30.6 TNF IL6 IL10 B2M
3 exanthem 30.6 TNF IL6 IL10
4 chronic graft versus host disease 30.5 IL1A IL10
5 esophagitis 30.5 TNF IL6 IL10
6 sclerosing cholangitis 30.5 TNF IL6 IL10
7 cholangitis 30.5 TNF IL6 IL10
8 cholangitis, primary sclerosing 30.5 TNF IL6 IL10
9 hemophagocytic lymphohistiocytosis 30.4 TNF IL10 B2M
10 appendicitis 30.3 TNF IL6 IL10
11 ileus 30.3 TNF IL6 IL10
12 neutropenia 30.3 TNFRSF1A TNF IL6 IL10
13 toxoplasmosis 30.2 TNF IL6 IL10
14 bronchiolitis obliterans 30.2 TNF IL6 IL10
15 bronchiolitis 30.2 TNF IL6 IL10
16 end stage renal disease 30.2 TNF IL6 IL10 B2M
17 burkitt lymphoma 30.2 TNF IL6 IL10 CASP8
18 myelitis 30.1 TNFRSF1A TNF IL6 IL10
19 sarcoidosis 1 30.0 TNFRSF1B TNF SLC11A1 LTA IL1A
20 posterior urethral valves 30.0 TNF IL6
21 peritonitis 30.0 TNF IL6 IL10 B2M
22 leishmaniasis 30.0 TNF SLC11A1 IL6 IL1A IL10
23 aspergillosis 29.9 TNF IL6 IL1R1 IL1A IL10
24 visceral leishmaniasis 29.9 TNF SLC11A1 LTA IL10RA IL10
25 myeloma, multiple 29.9 TNF IL6 IL10 CASP8 B2M
26 pulmonary fibrosis, idiopathic 29.9 TNF IL6 IL1R1 IL1A IL10
27 tonsillitis 29.9 TNF LTA IL6 IL1A IL10
28 pertussis 29.8 TNF IL6 IL1A IL10
29 thrombocytopenia 29.8 TNFRSF1A TNF LTA IL6 IL1A IL10
30 bacterial infectious disease 29.8 TNF SLC11A1 IL6 IL1R1 IL1A IL10
31 respiratory failure 29.7 TNF LTA IL6 IL1R1 IL1A IL10
32 disease by infectious agent 29.6 TNFRSF1A TNF SLC11A1 LTA IL6 IL10
33 cystic fibrosis 29.6 TNFRSF1A TNF IL6 IL1R1 IL1A IL10
34 ulcerative colitis 29.6 TNF IL6 IL1R1 IL10RA IL10
35 monoclonal gammopathy of uncertain significance 29.6 TNF LTA IL6 B2M
36 peripheral nervous system disease 29.5 TNF IL6 IL10 CASP8 B2M
37 leukemia, acute myeloid 29.5 TNF IL6 IL10 CASP8 B2M
38 uveitis 29.4 TNFRSF1A TNF LTA IL6 IL1R1 IL1A
39 lymphoma, non-hodgkin, familial 29.4 TNFRSF1A TNFRSF10A IL6 CASP8 B2M
40 colitis 29.2 TNFRSF1B TNF IL6 IL1R1 IL10RA IL10
41 aplastic anemia 29.2 TNFSF10 TNF LTA IL6 IL1R1 IL1A
42 myelodysplastic syndrome 28.7 TNFSF10 TNFRSF10A TNF IL6 IL1A IL10
43 immune deficiency disease 28.6 TNFRSF1A TNF LTA IL6 IL1R1 IL1A
44 leukemia, chronic lymphocytic 28.2 TNFSF10 TNFRSF10A TNF LTA IL6 IL10
45 lymphoproliferative syndrome 10.6
46 b-cell lymphoma 10.6
47 lymphoma, hodgkin, classic 10.5
48 plasmacytoma 10.5
49 intestinal perforation 10.4
50 punctate inner choroidopathy 10.4 TNF IL10

Graphical network of the top 20 diseases related to Post-Transplant Lymphoproliferative Disease:



Diseases related to Post-Transplant Lymphoproliferative Disease

Symptoms & Phenotypes for Post-Transplant Lymphoproliferative Disease

GenomeRNAi Phenotypes related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.73 CASP8 TNFRSF1B
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.73 CASP8 FADD IL10 IL1A LTA TNF
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.73 CASP8 IL1A
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.53 FADD IL10 IL1A LTA TNF TNFRSF10A
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.53 FADD IL10 LTA TNF TNFRSF1A TNFRSF1B
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.53 CASP8

MGI Mouse Phenotypes related to Post-Transplant Lymphoproliferative Disease:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.37 B2M CASP8 FADD IL10 IL10RA IL1A
2 cardiovascular system MP:0005385 10.34 B2M CASP8 FADD IL10 IL1A IL1R1
3 immune system MP:0005387 10.33 B2M CASP8 FADD IL10 IL10RA IL1A
4 homeostasis/metabolism MP:0005376 10.32 B2M CASP8 FADD IL10 IL10RA IL1A
5 endocrine/exocrine gland MP:0005379 10.3 B2M CASP8 FADD IL10 IL1R1 IL6
6 cellular MP:0005384 10.29 B2M CASP8 FADD IL10 IL10RA IL1R1
7 growth/size/body region MP:0005378 10.25 B2M CASP8 FADD IL10 IL1R1 IL6
8 digestive/alimentary MP:0005381 10.24 B2M FADD IL10 IL10RA IL1R1 IL6
9 mortality/aging MP:0010768 10.18 B2M CASP8 FADD IL10 IL1R1 IL6
10 liver/biliary system MP:0005370 10.14 B2M CASP8 FADD IL10 IL1R1 IL6
11 integument MP:0010771 10.13 B2M CASP8 IL10 IL1A IL1R1 IL6
12 neoplasm MP:0002006 10.03 B2M CASP8 IL10 IL1A IL1R1 IL6
13 muscle MP:0005369 9.92 CASP8 FADD IL10 IL1R1 IL6 TNF
14 nervous system MP:0003631 9.85 B2M CASP8 FADD IL10 IL1R1 IL6
15 respiratory system MP:0005388 9.56 CASP8 IL10 IL1R1 IL6 LTA TNF
16 skeleton MP:0005390 9.28 FADD IL10 IL1R1 IL6 LTA TNF

Drugs & Therapeutics for Post-Transplant Lymphoproliferative Disease

Drugs for Post-Transplant Lymphoproliferative Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Iron Approved Phase 3 7439-89-6 23925 29936
3
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Pancrelipase Approved, Investigational Phase 3 53608-75-6
6
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
7 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
8 Neurotransmitter Agents Phase 3
9 Excitatory Amino Acid Antagonists Phase 3
10 Anesthetics, Dissociative Phase 3
11 Cola Phase 3
12 Epoetin alfa Phase 3 113427-24-0
13 Hematinics Phase 3
14 Analgesics, Opioid Phase 3
15 Anesthetics Phase 3
16 Analgesics Phase 3
17 Anesthetics, Intravenous Phase 3
18 Anesthetics, General Phase 3
19 Narcotics Phase 3
20 ferric gluconate Phase 3
21 Iron Supplement Phase 3
22 Liver Extracts Phase 3
23 pancreatin Phase 3
24
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
25
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
26
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
27
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
28
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
29
Caspofungin Approved Phase 2 179463-17-3, 162808-62-0 468682 2826718
30
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
31
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
32
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
33
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
34
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
35
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
36
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
37
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
38
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
39
rituximab Approved Phase 2 174722-31-7 10201696
40
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
41
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
42
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
43
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643 439492
44
Mycophenolic acid Approved Phase 2 24280-93-1 446541
45
Busulfan Approved, Investigational Phase 2 55-98-1 2478
46
Lenograstim Approved, Investigational Phase 2 135968-09-1
47
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
48
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
49
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
50
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) Completed NCT01088724 Phase 4 fludarabine, cyclophosphamide, doxorubicin, rituximab
2 Cytotoxic T Cell Therapy for Post Transplant Lymphoproliferative Disease: Randomized Controlled Trial in Transplant Recipients Unknown status NCT00033475 Phase 3
3 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
5 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
6 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
7 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
8 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
9 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
10 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab Completed NCT03392142 Phase 3
12 Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy Recruiting NCT03394365 Phase 3
13 Phase II Study of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults With B-lymphocyte Antigen CD20 (CD20) Positive Post-Transplant Lymphoproliferative Disease (PTLD) Following Solid Organ Transplantation (SOT) Completed NCT00066469 Phase 2 cyclophosphamide;methylprednisolone;prednisone
14 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
15 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
16 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
17 Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma Completed NCT00436618 Phase 2 Everolimus
18 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
19 A Phase I/II Study: Zevalin Radioimmunotherapy for Patients With Post Transplant Lymphoproliferative Disease Following Solid Organ Transplantation Completed NCT00064246 Phase 1, Phase 2
20 Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD) Completed NCT01058239 Phase 2 bortezomib;rituximab
21 Treatment of Patients With Posttransplant Lymphoproliferative Disorder (PTLD) With a Sequential Treatment Consisting of Anti-CD20 Antibody Rituximab and CHOP+GCSF Chemotherapy (PTLD-1/3) Completed NCT00590447 Phase 2 rituximab monotherapy;sequential R-CHOP
22 Phase II Study of Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder (PTLD) Recruiting NCT04337827 Phase 2 Rituximab;Acalabrutinib
23 Multicenter Phase II Study of Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Type Monomorphic Post-transplant Lymphoproliferative Disorder Recruiting NCT02753062 Phase 2 bendamustine, rituximab
24 Ex-vivo Delivery of Rituximab to Prevent Post-transplant Lymphoproliferative Disease in Epstein-Barr Virus Mismatch Lung Transplant Recipients: A Pilot Trial Recruiting NCT04507477 Phase 1, Phase 2
25 A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD) Active, not recruiting NCT02900976 Phase 2
26 Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With 4 Courses of Rituximab SC Followed by 4 Courses of Rituximab SC, 4 Courses of Rituximab SC Combined With CHOP-21 or 6 Courses of Rituximab SC Combined With Alternating CHOP-21 and DHAOx: The PTLD-2 Trial Active, not recruiting NCT02042391 Phase 2 Rituximab sc;Rituximab sc consolidation;Rituximab sc combined with CHOP chemotherapy;Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx
27 A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-Matched Allogeneic Hematopoietic Transplantation for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Active, not recruiting NCT01434472 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Fludarabine
28 A Phase II Multicenter Open Label Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) in Patients Newly Diagnosed. Not yet recruiting NCT04138875 Phase 2 Rituximab;Brentuximab Vedotin;Bendamustine
29 Phase II Trial of Bortezomib and Rituximab for Patients With Post Transplant Lymphoproliferative Disorders (PTLD) Terminated NCT00869323 Phase 2 bortezomib
30 Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation Terminated NCT01118013 Phase 2 busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus
31 A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
32 Treatment of Patients With Posttransplant Lymphoproliferative Disorder (PTLD) With a Sequential Treatment Consisting of Anti-CD20 Antibody Rituximab and CHOP+GCSF Chemotherapy (Including 1st+2nd Amendment) Terminated NCT01458548 Phase 2 Rituximab;CHOP
33 A Phase II Study of Phenylbutyrate and Valganciclovir in Epstein-Barr Virus Positive Tumors Withdrawn NCT00387530 Phase 2 oral sodium phenylbutyrate;valganciclovir
34 Multi-Center, Prospective, Randomized, Double-Blinded, Controlled Clinical Trial to Evaluate the Safety and Effectiveness of an Antimicrobial Catheter Lock Solution in Maintaining Catheter Patency and Preventing Catheter Related Blood Stream Infections (CRBSI) Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
35 A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Patient-Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH (Id-KLH) and Administered With GM-CSF, in Patients With CNS Lymphoma Withdrawn NCT00621036 Phase 2 methotrexate;thiotepa
36 Phase II Study of Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD) Withdrawn NCT03086395 Phase 2 Obinutuzumab
37 A Phase Ib, Open-Label, Sequential, Dose-Finding, Study of AMG 706 in Combination With Gemcitabine to Treat Subjects With Solid Tumors Unknown status NCT00324597 Phase 1 gemcitabine hydrochloride;motesanib diphosphate
38 A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens Completed NCT01147991 Phase 1
39 A Combined Rising Single-Dose (RSD) and Rising Multiple-Dose (RMD) Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of KX2-391 in Patients With Advanced Malignancies That Are Refractory to Conventional Therapies Completed NCT00646139 Phase 1 Src kinase inhibitor KX2-391
40 Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumors and Lymphomas Completed NCT00734890 Phase 1 vandetanib
41 A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas Completed NCT01273090 Phase 1 imetelstat sodium
42 Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant Completed NCT00063648 Phase 1
43 Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CD19+ B-Cell Lymphoproliferative Neoplasms Recruiting NCT02153580 Phase 1 cyclophosphamide;Bendamustine Hydrochloride;Etoposide;Fludarabine Phosphate
44 A Pilot Study of EBV-TCR-T Cells in EB Virus Infection Diseases After HSCT Recruiting NCT04156217 Phase 1
45 Phase I Study of Oral ß-Glucan and Intravenous Rituximab Among Children and Adolescents With Relapsed CD20-Positive Lymphoma or Leukemia, or Post-Transplant Lymphoproliferative Disease Terminated NCT00087009 Phase 1
46 EBV as Therapeutic Target: A Pilot Study of Inducing and Targeting EBV-TK in EBV-Positive Lymphomas by Combination of Bortezomib and Ganciclovir Terminated NCT00093704 Phase 1 bortezomib + ganciclovir
47 Vaccination of Patients at High Risk for Post-Transplant Lymphoproliferative Disorder With a Photochemically Inactivated EBV-Infected B-Cell Vaccine Terminated NCT00278200 Phase 1
48 Virus Surveillance in Pediatric Solid Organ Transplant Recipients: Identifying Risk Factors for PTLD and Other Complications Post-Transplant Unknown status NCT00886158
49 Belatacept and Risk of PTLD in US Renal Transplant Recipients Unknown status NCT01656343 Calcineurin inhibitors (CNI);Belatacept
50 Fungemia Survey in Cancer Patients Completed NCT00445952

Search NIH Clinical Center for Post-Transplant Lymphoproliferative Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Post-Transplant Lymphoproliferative Disease:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Post-Transplant Lymphoproliferative Disease:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Post-Transplant Lymphoproliferative Disease

Anatomical Context for Post-Transplant Lymphoproliferative Disease

MalaCards organs/tissues related to Post-Transplant Lymphoproliferative Disease:

40
B Cells, Bone Marrow, T Cells, Lymph Node, Liver, Pancreas, Heart

Publications for Post-Transplant Lymphoproliferative Disease

Articles related to Post-Transplant Lymphoproliferative Disease:

(show top 50) (show all 2399)
# Title Authors PMID Year
1
Persistent chronic respiratory symptoms despite TB cure is poorly correlated with lung function. 61
33762069 2021
2
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. 61
32367180 2021
3
Post-transplant lymphoproliferative disorder after paediatric liver transplantation. 61
33222369 2021
4
The diagnostic and clinical significance of granulomas in gastrointestinal biopsies from haematopoietic transplant patients. 61
33217036 2021
5
Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders. 61
33793378 2021
6
Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation. 61
33547921 2021
7
Association between infectious event and de novo malignancy after heart transplantation. 61
33140148 2021
8
Post-transplant lymphoproliferative disorders after liver transplantation: A retrospective cohort study including 1,954 transplants. 61
33655645 2021
9
Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation. 61
33781531 2021
10
High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder. 61
33765256 2021
11
Recurrent Intestinal Perforation After Cessation of Immunosuppression in Posttransplant Lymphoproliferative Disease in Pediatric Liver Transplant Recipient. 61
33751328 2021
12
Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria. 61
33755341 2021
13
Factors Associated with Post-Transplant Active Epstein-Barr Virus Infection and Lymphoproliferative Disease in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis. 61
33808928 2021
14
Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report. 61
33773605 2021
15
EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide. 61
33675520 2021
16
De Novo Malignancies after Kidney Transplantation. 61
33782034 2021
17
Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report. 61
32762294 2021
18
Stage IV Classical Hodgkin Lymphoma-type Posttransplant Lymphoproliferative Disorder in a Pediatric Liver Transplant Patient: A Case Report and Review of the Literature. 61
33769384 2021
19
Serum free light chains in solid organ transplant recipients. 61
33715217 2021
20
Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review. 61
33774079 2021
21
Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder. 61
33704812 2021
22
Primary post-transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients. 61
33764500 2021
23
Prognostic superiority of International Prognostic Index over [18F]FDG PET/CT volumetric parameters in post-transplant lymphoproliferative disorder. 61
33738643 2021
24
Outcomes of kidney retransplantation in recipients with prior posttransplant lymphoproliferative disorders: An analysis of the 2000-2019 UNOS/OPTN database. 61
33128832 2021
25
Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient. 61
33612072 2021
26
Spontaneous regression of central nervous system posttransplant lymphoproliferative disease: A case report. 61
33578612 2021
27
Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra. 61
33544319 2021
28
Distinct immunopathological mechanisms of EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. 61
33621411 2021
29
Post-transplant malignancies in pediatric organ transplant recipients. 61
33111463 2021
30
Resumé of the challenges and burden of living with transplanted hearts for >31 years. 61
33708489 2021
31
Signaling pathways of EBV-induced oncogenesis. 61
33549103 2021
32
Evolution of pediatric gastrointestinal Ulcer disease: Is acute surgical intervention relevant? 61
33678404 2021
33
CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. 61
33089906 2021
34
Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein-Barr Virus (EBV) Assessments-A Single Tertiary Referral Center Experience and Review of Literature. 61
33669937 2021
35
Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders-diffuse large B-cell lymphoma. 61
33536508 2021
36
Characteristics of T and NK-cell Lymphomas After Renal Transplantation: a French National Multicentric Cohort Study. 61
33560724 2021
37
Post-transplant lymphoproliferative disorder as a cause of oesophageal ulceration and stricture: case report and literature review. 61
33648984 2021
38
Malignant Post-Transplant Lymphoproliferative Disorder of Nasopharynx in Myelodysplastic Disorder. 61
33671238 2021
39
Post-transplant lymphoproliferative disorder with cutaneous involvement: A series of four cases. 61
33217057 2021
40
Immunological Risk Factors in Paediatric Kidney Transplantation. 61
33654694 2021
41
Cumulative incidence of solid and hematological De novo malignancy after liver transplantation in a multicentre cohort. 61
33482364 2021
42
Epstein-Barr Virus-Associated Post-transplant Lymphoproliferative Disease. 61
33200367 2021
43
Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation. 61
32933363 2021
44
Infectious complications during immunochemotherapy of post-transplantation lymphoproliferative disease-can we decrease the risk? Two case reports and review of literature. 61
33553416 2021
45
Facial Paralysis From Post-Transplant Lymphoproliferative Disorder. 61
33443973 2021
46
Relapsed Chronic Lymphocytic Leukaemia with Concomitant Extensive Chronic Graft versus Host Disease after Allogeneic Haematopoietic Stem Cell Transplantation Successfully Treated with Oral Venetoclax. 61
33552611 2021
47
Application of contrast-enhanced ultrasound in the diagnosis of post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation: A case report. 61
33466157 2021
48
Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge. 61
33401266 2021
49
Epstein-Barr virus-associated post-transplant lymphoproliferative disease during dasatinib treatment occurred 10 years after umbilical cord blood transplantation. 61
33518401 2021
50
Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. 61
33631963 2021

Variations for Post-Transplant Lymphoproliferative Disease

Expression for Post-Transplant Lymphoproliferative Disease

Search GEO for disease gene expression data for Post-Transplant Lymphoproliferative Disease.

Pathways for Post-Transplant Lymphoproliferative Disease

Pathways related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 TNFRSF1B TNFRSF1A TNF SLC11A1 LTA IL6
2
Show member pathways
13.86 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A TNF LTA
3
Show member pathways
13.78 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A TNF LTA
4
Show member pathways
13.71 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A TNF LTA
5
Show member pathways
13.59 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A TNF LTA
6
Show member pathways
13.47 TNFRSF1B TNFRSF1A TNF IL6 IL1A FADD
7
Show member pathways
13.43 TNFRSF1B TNFRSF1A TNF LTA IL6 IL1R1
8
Show member pathways
13.33 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A TNF LTA
9
Show member pathways
13.27 TNFSF10 TNFRSF1A TNFRSF10A TNF IL6 IL10
10
Show member pathways
13.15 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A TNF LTA
11
Show member pathways
13.1 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A TNF LTA
12
Show member pathways
13 TNFRSF1B TNFRSF1A TNF IL6 IL1R1 IL10RA
13
Show member pathways
12.99 TNFRSF1A TNF IL6 FADD CASP8
14
Show member pathways
12.95 TNF LTA IL6 IL1A IL10 FADD
15 12.9 TNFRSF1A TNF LTA IL6 FADD CASP8
16
Show member pathways
12.84 TNFSF10 TNFRSF1A TNFRSF10A TNF IL6 IL1R1
17
Show member pathways
12.84 TNFSF10 TNFRSF1A TNFRSF10A TNF IL6 IL1A
18
Show member pathways
12.82 TNFRSF1B TNFRSF1A TNF LTA IL6
19 12.8 TNFRSF1A TNF IL1R1 IL1A CASP8
20
Show member pathways
12.8 TNFRSF1B TNFRSF1A TNF LTA IL6 IL1R1
21
Show member pathways
12.76 TNFRSF1B TNFRSF1A TNF LTA FADD CASP8
22
Show member pathways
12.75 TNFRSF1B TNFRSF1A TNF LTA IL1R1 IL1A
23
Show member pathways
12.71 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A TNF LTA
24
Show member pathways
12.68 TNFRSF1B TNFRSF1A TNF IL10RA IL10
25
Show member pathways
12.66 TNF IL6 IL1R1 IL1A IL10
26 12.62 TNFRSF1B TNFRSF1A TNF IL10 B2M
27
Show member pathways
12.6 TNF IL6 IL1A IL10
28
Show member pathways
12.59 TNF IL6 IL10RA IL10
29 12.46 TNFRSF1A TNF LTA IL6 IL1R1 B2M
30
Show member pathways
12.44 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A TNF FADD
31
Show member pathways
12.38 TNF IL6 FADD CASP8
32
Show member pathways
12.38 TNFRSF1A TNF IL1A IL10RA IL10 CASP8
33
Show member pathways
12.35 TNF IL6 IL1R1 IL1A
34
Show member pathways
12.35 TNFSF10 TNFRSF10A FADD CASP8
35 12.35 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A TNF FADD
36
Show member pathways
12.32 TNF LTA IL6 IL1A IL10
37
Show member pathways
12.32 TNFRSF1A TNF IL1A FADD CASP8
38 12.29 TNF IL6 FADD CASP8
39
Show member pathways
12.28 TNFSF10 TNFRSF1A TNFRSF10A TNF IL1A FADD
40
Show member pathways
12.27 TNF IL6 IL10 CASP8
41 12.24 TNF IL6 IL1A IL10
42 12.2 TNFRSF1A TNF FADD CASP8
43
Show member pathways
12.19 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A TNF LTA
44 12.18 TNFRSF1A TNF IL6 IL1A IL10RA IL10
45 12.16 TNFRSF1A TNF IL1R1 IL1A
46
Show member pathways
12.14 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A TNF LTA
47 12.12 TNFRSF1A TNF IL1R1 IL1A
48
Show member pathways
12.1 TNFRSF1A TNF FADD CASP8
49 12.1 TNFRSF1B TNF IL6 IL1A IL10
50 12.09 TNF IL6 IL1R1 IL1A

GO Terms for Post-Transplant Lymphoproliferative Disease

Cellular components related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.17 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A TNF SLC11A1
2 extracellular space GO:0005615 9.86 TNFSF10 TNFRSF1A TNF LTA IL6 IL1A
3 cell surface GO:0009986 9.85 TNFRSF1A TNFRSF10A TNF IL1R1 B2M
4 extracellular region GO:0005576 9.65 TNFSF10 TNFRSF1B TNFRSF1A TNF LTA IL6
5 death-inducing signaling complex GO:0031264 9.4 FADD CASP8
6 ripoptosome GO:0097342 9.37 FADD CASP8
7 CD95 death-inducing signaling complex GO:0031265 9.32 FADD CASP8
8 tumor necrosis factor receptor superfamily complex GO:0002947 9.16 TNFRSF1B TNFRSF1A
9 membrane raft GO:0045121 9.1 TNFRSF1B TNFRSF1A TNFRSF10A TNF FADD CASP8

Biological processes related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.28 TNFSF10 TNFRSF1A TNFRSF10A LTA IL6 IL1R1
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 TNFRSF1A TNF SLC11A1 IL6 IL1A IL10
3 apoptotic process GO:0006915 10.11 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A LTA IL1A
4 inflammatory response GO:0006954 10.04 TNFRSF1B TNFRSF1A TNF SLC11A1 IL6 IL1R1
5 positive regulation of apoptotic process GO:0043065 10.02 TNFSF10 TNFRSF10A TNF LTA IL6 FADD
6 defense response to bacterium GO:0042742 10.01 TNFRSF1A TNF SLC11A1 IL10
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.98 TNFSF10 TNFRSF1A TNF FADD CASP8
8 cellular response to lipopolysaccharide GO:0071222 9.97 TNFRSF1B TNF IL6 IL1A IL10
9 tumor necrosis factor-mediated signaling pathway GO:0033209 9.93 TNFRSF1B TNFRSF1A TNF LTA
10 response to lipopolysaccharide GO:0032496 9.93 TNFRSF1B SLC11A1 LTA IL10RA IL10 CASP8
11 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.92 TNFSF10 TNFRSF10A TNF FADD CASP8
12 positive regulation of DNA-binding transcription factor activity GO:0051091 9.91 TNF IL6 IL10
13 cell surface receptor signaling pathway GO:0007166 9.91 TNFSF10 TNFRSF1B TNFRSF1A TNFRSF10A IL1R1 FADD
14 defense response to Gram-positive bacterium GO:0050830 9.9 TNF LTA IL6
15 positive regulation of interleukin-6 production GO:0032755 9.89 TNF IL6 IL1A
16 positive regulation of tumor necrosis factor production GO:0032760 9.89 IL6 IL1A FADD
17 cellular response to mechanical stimulus GO:0071260 9.89 TNFRSF1A TNFRSF10A FADD CASP8
18 apoptotic signaling pathway GO:0097190 9.87 TNF FADD CASP8
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.87 TNFRSF1A TNF IL6
20 positive regulation of cytokine production GO:0001819 9.87 TNF SLC11A1 IL1A IL10
21 response to glucocorticoid GO:0051384 9.86 TNF IL6 IL10
22 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.86 TNFSF10 TNFRSF10A FADD CASP8
23 positive regulation of interleukin-8 production GO:0032757 9.84 TNF IL6 FADD
24 humoral immune response GO:0006959 9.84 TNF LTA IL6
25 positive regulation of JAK-STAT cascade GO:0046427 9.84 TNF IL6 IL10RA IL10
26 positive regulation of interleukin-1 beta production GO:0032731 9.83 TNF IL6 CASP8
27 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.83 TNFRSF1B TNFRSF1A TNF
28 positive regulation of interferon-gamma production GO:0032729 9.83 TNF SLC11A1 LTA IL1R1 FADD
29 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.8 TNFRSF1A TNF CASP8
30 positive regulation of extrinsic apoptotic signaling pathway GO:2001238 9.79 TNFSF10 TNF FADD
31 regulation of synapse organization GO:0050807 9.79 TNF IL10RA IL10
32 negative regulation of neurogenesis GO:0050768 9.78 TNF IL6 B2M
33 positive regulation of glial cell proliferation GO:0060252 9.77 TNF LTA IL6
34 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.73 TNFRSF1B TNF
35 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.73 TNF IL10
36 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.73 TNF IL6
37 activation of cysteine-type endopeptidase activity GO:0097202 9.73 FADD CASP8
38 positive regulation of macrophage differentiation GO:0045651 9.73 FADD CASP8
39 positive regulation of ceramide biosynthetic process GO:2000304 9.72 TNFRSF1A TNF
40 positive regulation of neuroinflammatory response GO:0150078 9.72 TNF IL6
41 toll-like receptor 3 signaling pathway GO:0034138 9.72 FADD CASP8
42 regulation of neuroinflammatory response GO:0150077 9.72 TNFRSF1B IL6
43 TRAIL-activated apoptotic signaling pathway GO:0036462 9.72 TNFRSF10A FADD CASP8
44 extrinsic apoptotic signaling pathway GO:0097191 9.72 TNFRSF1B TNFRSF10A TNF FADD CASP8
45 response to molecule of bacterial origin GO:0002237 9.71 IL10 B2M
46 regulation of establishment of endothelial barrier GO:1903140 9.71 TNFRSF1A TNF
47 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.71 TNFSF10 TNFRSF10A FADD CASP8
48 cellular response to nicotine GO:0071316 9.7 TNF B2M
49 negative regulation of lipid storage GO:0010888 9.7 TNF IL6
50 necroptotic signaling pathway GO:0097527 9.7 TNF FADD

Molecular functions related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.98 TNFSF10 TNFRSF1A TNFRSF10A TNF FADD CASP8
2 death receptor binding GO:0005123 9.48 FADD CASP8
3 tumor necrosis factor-activated receptor activity GO:0005031 9.46 TNFRSF1B TNFRSF1A
4 protease binding GO:0002020 9.46 TNFRSF10A TNF IL1R1 FADD
5 cytokine activity GO:0005125 9.43 TNFSF10 TNF LTA IL6 IL1A IL10
6 tumor necrosis factor receptor superfamily binding GO:0032813 9.4 TNFSF10 FADD
7 TRAIL binding GO:0045569 9.37 TNFSF10 TNFRSF10A
8 tumor necrosis factor binding GO:0043120 9.32 TNFRSF1B TNFRSF1A
9 death effector domain binding GO:0035877 9.26 FADD CASP8
10 tumor necrosis factor receptor binding GO:0005164 9.02 TNFSF10 TNF LTA FADD CASP8

Sources for Post-Transplant Lymphoproliferative Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....